KR960700726A - 수정의 방지 또는 억제방법(method of preventing of inhibting fertilization) - Google Patents

수정의 방지 또는 억제방법(method of preventing of inhibting fertilization) Download PDF

Info

Publication number
KR960700726A
KR960700726A KR1019950703491A KR19950703491A KR960700726A KR 960700726 A KR960700726 A KR 960700726A KR 1019950703491 A KR1019950703491 A KR 1019950703491A KR 19950703491 A KR19950703491 A KR 19950703491A KR 960700726 A KR960700726 A KR 960700726A
Authority
KR
South Korea
Prior art keywords
antiprogestin
amount
mammal
kit
tablets
Prior art date
Application number
KR1019950703491A
Other languages
English (en)
Other versions
KR100232833B1 (ko
Inventor
그래이 디이. 허드겐
Original Assignee
데이비드 이. 디얼
헴프톤로드 메디칼칼리지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데이비드 이. 디얼, 헴프톤로드 메디칼칼리지 filed Critical 데이비드 이. 디얼
Publication of KR960700726A publication Critical patent/KR960700726A/ko
Application granted granted Critical
Publication of KR100232833B1 publication Critical patent/KR100232833B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Catching Or Destruction (AREA)
  • Pens And Brushes (AREA)
  • Fertilizers (AREA)
  • Fats And Perfumes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

월경주기의 규칙을 지속시키는 반면에, 배란을 방지하기에는 불충분하며 수정을 억제하기에는 충분한 수정억제량으로 배란성 포유동물에게 안티프로제스틴의 수정억제량을 복용시키므로써 난모세포의 수정이 방지 또는 억제된다.

Description

수정의 방지 또는 억제방법(METHOD OF PREVENTING OF INHIBTING FERTILIZATION)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (18)

  1. 포유동물의 배란을 방지하거나 또는 난소월경주기의 규칙을 방해하기에는 불충분한 양으로 배란성 포유동물에게 안티프로제스틴의 수정억제량을 복용하는 난모세포의 숙성 및/또는 수정을 억제하는 방법.
  2. 제1항에 있어서, 월경주기동안 안티프로제스틴을 주기적으로 복수회 복용하는 방법.
  3. 제1항에 있어서, 월경주기의 실질적 부분동안 안티프로제스틴을 매일 복용하는 방법.
  4. 제3항에 있어서, 그 복용이 경구복용인 방법.
  5. 제1항에 있어서, 그 복용이 경구복용인 방법.
  6. 제1항에 있어서, 그 복용이 양식이 저장소에 의한 방법.
  7. 제1항에 있어서, 포유동물에 대한 복용은 약 0.01~1㎎의 안티프로제스틴을 함유하는 방법.
  8. 제7항에 있어서, 상기한 양이 약 0.05~0.5㎎인 방법.
  9. 제1항에 있어서, 상기한 포유동물이 인간인 방법.
  10. 제1항에 있어서, 안티프로제스틴이 프로제스테론 수용체 길항약인 방법.
  11. 제9항에 있어서, 상기한 안티프로제스테론이 RU 486인 방법.
  12. 제1항에 있어서, 포유동물에게 의인성 프로제스틴은 복용하지 않는 방법.
  13. 안티프로제스틴은 연속적으로 복용하는 경우, 3이상의 비인접한 정제는 각각 안티프로제스틴의 수정억제량을 함유하며, 상기한 수정억제량은 포유동물의 배란을 방지하거나 또는 난소월경주기의 규칙을 방해하기에 불충분한 양으로 이루어진 약 20정제 이상을 함유하는 키트.
  14. 제13항에 있어서, 상기한 약 20정제의 각각은 상기한 안티프로제스틴의 수정억제량을 함유하는 키트.
  15. 제13항에 있어서, 상기한 양이 약 0.01~1㎎인 키트.
  16. 제15항에 있어서, 상기한 양이 약 0.05~0.5㎎인 키트.
  17. 제16항에 있어서, 상기한 안티프로제스틴이 RU 486인 키트.
  18. 제13항에 있어서, 약 20정제 이상이 안티프로제스틴의 수정억제량을 함유하는 약 28정제를 함유하는 키트.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950703491A 1993-02-19 1994-02-18 수정의 방지 또는 억제방법 KR100232833B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8/019791 1993-02-19
US08/019,791 US5516769A (en) 1993-02-19 1993-02-19 Method of inhibiting fertilization
US08/019,791 1993-02-19
PCT/US1994/001804 WO1994018982A1 (en) 1993-02-19 1994-02-18 Method of preventing or inhibiting fertilization

Publications (2)

Publication Number Publication Date
KR960700726A true KR960700726A (ko) 1996-02-24
KR100232833B1 KR100232833B1 (ko) 1999-12-01

Family

ID=21795040

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950703491A KR100232833B1 (ko) 1993-02-19 1994-02-18 수정의 방지 또는 억제방법

Country Status (24)

Country Link
US (1) US5516769A (ko)
EP (2) EP1159965B1 (ko)
JP (1) JP3054780B2 (ko)
KR (1) KR100232833B1 (ko)
AT (2) ATE286734T1 (ko)
AU (1) AU692150B2 (ko)
BG (1) BG62431B1 (ko)
BR (1) BR9406666A (ko)
CA (1) CA2156493C (ko)
CZ (1) CZ294325B6 (ko)
DE (2) DE69434239T2 (ko)
DK (2) DK1159965T3 (ko)
ES (1) ES2231356T3 (ko)
FI (1) FI114687B (ko)
HU (1) HU221162B1 (ko)
NO (1) NO307916B1 (ko)
NZ (1) NZ262998A (ko)
PL (1) PL175440B1 (ko)
PT (2) PT684825E (ko)
RO (1) RO118565B1 (ko)
RU (1) RU2139055C1 (ko)
SK (1) SK282068B6 (ko)
UA (1) UA41351C2 (ko)
WO (1) WO1994018982A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US7704983B1 (en) 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
DE4344463A1 (de) * 1993-12-22 1995-06-29 Schering Ag Kombinationsprodukt zur Kontrazeption
CO5190694A1 (es) 1999-08-31 2002-08-29 Jenapharm Gmbh And Co Kg Mesoprogestinas (moduladores de receptores de progesterona) como componentes de anticonceptivos femeninos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3890356A (en) * 1973-03-26 1975-06-17 Richardson Merrell Inc 7-Alkyl-{66 {hu 3,5{b -steroids
US3928398A (en) * 1973-11-01 1975-12-23 Richardson Merrell Inc Derivatives of 7{60 -methylestr-4-en-3{60 ,17{62 -diol
US4000273A (en) * 1973-11-01 1976-12-28 Richardson-Merrell Inc. Method for the control of fertility
US4416822A (en) * 1982-07-09 1983-11-22 The Upjohn Company 17β-Difluoromethyl steroids
IL68222A (en) * 1983-03-24 1987-02-27 Yeda Res & Dev Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity
AU572589B2 (en) * 1983-12-14 1988-05-12 Upjohn Company, The 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives

Also Published As

Publication number Publication date
UA41351C2 (uk) 2001-09-17
CA2156493C (en) 2002-10-29
BR9406666A (pt) 1996-01-23
NO953242D0 (no) 1995-08-17
BG62431B1 (bg) 1999-11-30
CA2156493A1 (en) 1994-09-01
DE69434239D1 (de) 2005-02-17
DE69434239T2 (de) 2006-03-30
DE69430732D1 (de) 2002-07-11
PT1159965E (pt) 2005-03-31
NZ262998A (en) 1997-06-24
CZ205095A3 (en) 1996-01-17
BG99867A (bg) 1996-04-30
EP1159965A3 (en) 2002-05-22
HUT72079A (en) 1996-03-28
PL175440B1 (pl) 1998-12-31
DE69430732T2 (de) 2002-10-24
AU6299294A (en) 1994-09-14
RU2139055C1 (ru) 1999-10-10
SK282068B6 (sk) 2001-10-08
FI114687B (fi) 2004-12-15
HU221162B1 (en) 2002-08-28
ES2231356T3 (es) 2005-05-16
DK1159965T3 (da) 2005-05-23
CZ294325B6 (cs) 2004-11-10
PT684825E (pt) 2002-10-31
NO953242L (no) 1995-08-17
EP1159965B1 (en) 2005-01-12
FI953878A (fi) 1995-08-17
KR100232833B1 (ko) 1999-12-01
SK101395A3 (en) 1997-04-09
FI953878A0 (fi) 1995-08-17
JPH08510992A (ja) 1996-11-19
ATE286734T1 (de) 2005-01-15
EP0684825B1 (en) 2002-06-05
RO118565B1 (ro) 2003-07-30
JP3054780B2 (ja) 2000-06-19
EP1159965A2 (en) 2001-12-05
ATE218347T1 (de) 2002-06-15
EP0684825A4 (en) 1998-01-14
NO307916B1 (no) 2000-06-19
DK0684825T3 (da) 2002-07-15
EP0684825A1 (en) 1995-12-06
AU692150B2 (en) 1998-06-04
WO1994018982A1 (en) 1994-09-01
PL310357A1 (en) 1995-12-11
US5516769A (en) 1996-05-14

Similar Documents

Publication Publication Date Title
KR960700727A (ko) 호르몬 대체 치료(hormone replacement therapy)
KR920011514A (ko) 프로게스토겐만을 함유하는 피임제
AU1537095A (en) Therapeutic agents containing thyroid hormones
ES2087964T3 (es) Contraceptivos orales bajos en estrogenos.
KR960706344A (ko) 호르몬 피임 및/또는 여드름 치료 수단 및 방법(means and method for hormonal contraception and/or the treatment of acne)
NO179696C (no) Ovulasjonshemmende middel for hormonell antikonsepsjon
ATE239483T1 (de) Pharmazeutisches kombinationspräparat, kit und methode zur hormonalen kontrazeption
YU49026B (sh) UPOTREBA 17 Гџ -(N-TERC-BUTILKARBAMOIL)-4-AZA-5-ALFA-ANDROST-1-3-ON ZA PROIZVODNJU LEKA ZA TRETIRANJE ANDROGENE ALOPECIJE
NO986104D0 (no) Progesteron-anti-progesteron regimer
KR960700061A (ko) 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence)
PT868188E (pt) Kit para a contracepcao em mamiferos femininos consistindo numa combinacao de gestagenio e estrogenio
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
UY24308A1 (es) Tabletas exentas de aglutinante que contienen tramadol o una sal de tramadol, para administracion oral
BG101427A (en) Competitive progesterone antagonists for regulating female fertility as required
KR960700726A (ko) 수정의 방지 또는 억제방법(method of preventing of inhibting fertilization)
BR0008057A (pt) Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada
KR940005275A (ko) 1α,24(R)-디히드록시-22(E)-데히드로-비타민D₃로 이루어지는 골다공증 치료용 제약 조성물
KR940005276A (ko) 1α, 25-디히드록시-22(E)-데히드로-비타민 D₃로 이루어지는 골다공증 치료용 제약 조성물
RU2225714C2 (ru) Новый набор противозачаточных средств
MX2007009061A (es) Preparacion farmaceutica para la anticoncepcion oral.
RU95118417A (ru) Способ предупреждения или задержки оплодотворения
DK1462107T3 (da) Fremgangsmåde til kvindelig kontraception og kit til anvendelse i en sådan fremgangsmåde
De Prospo et al. Effects of p-chlorophenylalanine on pineal serotonin and 131I uptake by the thyroid glands of rats
Saiduddin Compensatory ovarian hypertrophy after unilateral ovariectomy in hypothyroid rats
PE105899A1 (es) Progestagenos cristalinos

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120423

Year of fee payment: 14

FPAY Annual fee payment

Payment date: 20130508

Year of fee payment: 15

EXPY Expiration of term